Jason White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jason White has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Glaucia H. C. Prado
Department of Chemical and Materials Engineering, University of Alberta, 9211 116th Street, Edmonton, Alberta T6G 1H9, Canada
2 shared publications - Ahmet Palazoglu
Department of Chemical Engineering, University of California, Davis, CA 95616, USA
1 shared publication Calem Nist
University of California, Davis
1 shared publication- Colleen Elizabeth Bronner
Center for Geotechnical Modeling, Department of Civil and Environmental Engineering, University of California, Davis, Davis, CA, United States
1 shared publication Corrin Clemons
University of California, Davis
1 shared publicationD. E. Peterson
1 shared publication
Latest Publications
- 3 August 2024
- Published by American Society for Engineering Education
A Wellness Course for Engineering Students
- 3 August 2024
- Published by American Society for Engineering Education
A Wellness Course for Engineering Students
- 25 March 2017
- Published by Springer Nature
- p. 53-66
Integration of Reaction Kinetics Theory and Gene Expression Programming to Infer Reaction Mechanism
- 25 March 2017
- Published by Springer Nature
- p. 53-66
Integration of Reaction Kinetics Theory and Gene Expression Programming to Infer Reaction Mechanism
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e19690
Optimizing personalized treatment of oral mucositis secondary to cancer therapy through systems biology.
E19690 Background: Oral mucositis (OM) can result in clinically significant adverse outcomes that require high resource utilization. Clinical trials for mucositis drug development have typically incorporated a cohort-based methodology. However, patients vary considerably in risk and severity of OM. In addition, the modeling for OM pathobiology is complex and includes up-regulation of NF-kB and TNF-a. We therefore tested the hypothesis that an individual patient-oriented systems biology approach to mucositis management will maximize treatment efficacy, while reducing drug dosage. Methods: A mathematical model of the biomolecular reaction network describing the dynamics of NF-kB and TNF-a up-regulation was developed using data derived from published studies. To represent inter-subject variation, 10,000 in silico subjects were generated, with the reaction rate constants of each being randomly distributed by up to ± 30% relative to a pre-specified base-case. OM treatment was optimized using a genetic algorithm designed to down-regulate TNF-a levels to a pre-determined level using the minimum possible drug dosage. Two in silico subjects who deviated from average cohort behavior were randomly selected for comparison. Results: When optimized for the individual, required drug dosage for the first in silico subject was 20% of the cohort-optimized dosage on average. However, TNF-a levels for the individual were maintained within 5% of the average case. The optimal drug treatment for the second subject consisted of the maximum allowable drug dosage, representing a 10-fold increase versus the cohort-optimized case. Even with maximum drug dosage, TNF-a levels were at least 7.5-fold higher than the average case. In all cases, NF-kB dynamic behavior reflected that seen for TNF-a. Conclusions: Individually-optimized OM treatment may improve therapeutic efficacy in selected patients, while limiting drug dosage and associated side-effects. Supported by NIH Career Development Award K23DE016946 and NIH grant P41RR013186.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e19690
Optimizing personalized treatment of oral mucositis secondary to cancer therapy through systems biology.
E19690 Background: Oral mucositis (OM) can result in clinically significant adverse outcomes that require high resource utilization. Clinical trials for mucositis drug development have typically incorporated a cohort-based methodology. However, patients vary considerably in risk and severity of OM. In addition, the modeling for OM pathobiology is complex and includes up-regulation of NF-kB and TNF-a. We therefore tested the hypothesis that an individual patient-oriented systems biology approach to mucositis management will maximize treatment efficacy, while reducing drug dosage. Methods: A mathematical model of the biomolecular reaction network describing the dynamics of NF-kB and TNF-a up-regulation was developed using data derived from published studies. To represent inter-subject variation, 10,000 in silico subjects were generated, with the reaction rate constants of each being randomly distributed by up to ± 30% relative to a pre-specified base-case. OM treatment was optimized using a genetic algorithm designed to down-regulate TNF-a levels to a pre-determined level using the minimum possible drug dosage. Two in silico subjects who deviated from average cohort behavior were randomly selected for comparison. Results: When optimized for the individual, required drug dosage for the first in silico subject was 20% of the cohort-optimized dosage on average. However, TNF-a levels for the individual were maintained within 5% of the average case. The optimal drug treatment for the second subject consisted of the maximum allowable drug dosage, representing a 10-fold increase versus the cohort-optimized case. Even with maximum drug dosage, TNF-a levels were at least 7.5-fold higher than the average case. In all cases, NF-kB dynamic behavior reflected that seen for TNF-a. Conclusions: Individually-optimized OM treatment may improve therapeutic efficacy in selected patients, while limiting drug dosage and associated side-effects. Supported by NIH Career Development Award K23DE016946 and NIH grant P41RR013186.